Exelixis (EX9) Stock Forecast & Price Target
1 Followers
EX9 Analyst Ratings
Moderate Buy
5Buy9Hold1Sell
Based on 15 analysts giving stock ratings to Exelixis in the past 3 months
EX9 Stock 12 Month Forecast
Average Price Target
EUR 52.97▼(-14.03% Downside)Based on 15 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is EUR 52.97 with a high forecast of EUR 69.84 and a low forecast of EUR 36.71. The average price target represents a -14.03% change from the last price of EUR 61.61.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 69.84
AverageEUR 52.97
LowEUR 36.71
Highest Price TargetHighestEUR 69.84Average Price TargetEUR 52.97Lowest Price TargetLowestEUR 36.71
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Robert Burns | H.C. Wainwright | EUR 50.14→EUR 69.84 | buy | 13.36%Upside | Reiterated | 11/02/26 | ||
| Etzer Darout | Barclays | EUR 43.87→EUR 48.35 | hold | -21.52%Downside | Reiterated | 10/30/26 | ||
| David Lebowitz | BMO Capital | EUR 48.35→EUR 53.72 | hold | -12.80%Downside | Assigned | 10/30/26 | ||
| Sean Laaman | Morgan Stanley | EUR 47.46→EUR 53.72 | hold | -12.80%Downside | Assigned | 10/30/26 | ||
| Yaron Werber | TD Cowen | EUR 49.25→EUR 68.05 | buy | 10.45%Upside | Reiterated | 10/30/26 | ||
| Gregory Renza | Truist Financial | EUR 48.35→EUR 53.72 | hold | -12.80%Downside | Reiterated | 10/30/26 | ||
| Stephen Willey | Stifel Nicolaus | EUR 45.67 | hold | -25.88%Downside | Reiterated | 10/30/26 | ||
| Leonid Timashev | RBC Capital | EUR 45.67→EUR 51.93 | hold | -15.71%Downside | Assigned | 10/29/26 | ||
 Unknown AnalystNot Ranked | Guggenheim | ― | hold | ― | Reiterated | 10/29/26 | ||
| Silvan Tuerkcan | Citizens JMP | EUR 49.25→EUR 58.20 | buy | -5.53%Downside | Reiterated | 10/19/26 | ||
| Jason Gerberry | Bank of America Securities | EUR 36.71 | sell | -40.41%Downside | Reiterated | 10/09/26 | ||
| Andy Hsieh | William Blair | ― | buy | ― | Reiterated | 09/11/26 | ||
| Eva Fortea Verdejo | Wells Fargo | EUR 43.87→EUR 44.77 | hold | -27.33%Downside | Assigned | 08/06/26 | ||
| Andrew Berens | Leerink Partners | EUR 46.56 | hold | -24.43%Downside | Downgraded | 08/06/26 | ||
| Paul Choi | Goldman Sachs | EUR 57.31 | buy | -6.99%Downside | Reiterated | 08/05/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Robert BurnsH.C. Wainwright | BuyReiteratedEUR 50.14→EUR 69.84 | 11/02/26 | 13.36%Upside | ||
| Etzer DaroutBarclays | HoldReiteratedEUR 43.87→EUR 48.35 | 10/30/26 | -21.52%Downside | ||
| David LebowitzBMO Capital | HoldAssignedEUR 48.35→EUR 53.72 | 10/30/26 | -12.80%Downside | ||
| Sean LaamanMorgan Stanley | HoldAssignedEUR 47.46→EUR 53.72 | 10/30/26 | -12.80%Downside | ||
| Yaron WerberTD Cowen | BuyReiteratedEUR 49.25→EUR 68.05 | 10/30/26 | 10.45%Upside | ||
| Gregory RenzaTruist Financial | HoldReiteratedEUR 48.35→EUR 53.72 | 10/30/26 | -12.80%Downside | ||
| Stephen WilleyStifel Nicolaus | HoldReiteratedEUR 45.67 | 10/30/26 | -25.88%Downside | ||
| Leonid TimashevRBC Capital | HoldAssignedEUR 45.67→EUR 51.93 | 10/29/26 | -15.71%Downside | ||
| Unknown AnalystGuggenheimNot Ranked | HoldReiterated | 10/29/26 | ― | ||
| Silvan TuerkcanCitizens JMP | BuyReiteratedEUR 49.25→EUR 58.20 | 10/19/26 | -5.53%Downside | ||
| Jason GerberryBank of America Securities | SellReiteratedEUR 36.71 | 10/09/26 | -40.41%Downside | ||
| Andy HsiehWilliam Blair | BuyReiterated | 09/11/26 | ― | ||
| Eva Fortea VerdejoWells Fargo | HoldAssignedEUR 43.87→EUR 44.77 | 08/06/26 | -27.33%Downside | ||
| Andrew BerensLeerink Partners | HoldDowngradedEUR 46.56 | 08/06/26 | -24.43%Downside | ||
| Paul ChoiGoldman Sachs | BuyReiteratedEUR 57.31 | 08/05/26 | -6.99%Downside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Exelixis
3 Months
Success Rate18/25 ratings generated profit
72%
Average Return
+9.20%
Copying Yaron Werber's trades and holding each position for 3 Months would result in 72.00% of your transactions generating a profit, with an average return of +9.20% per trade.
1 Year
Success Rate35/39 ratings generated profit
90%
Average Return
+28.18%
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 89.74% of your transactions generating a profit, with an average return of +28.18% per trade.
2 Years
Success Rate32/39 ratings generated profit
82%
Average Return
+68.51%
Copying Silvan Tuerkcan's trades and holding each position for 2 Years would result in 82.05% of your transactions generating a profit, with an average return of +68.51% per trade.
EX9 Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 7 | 6 | 6 | 6 | 4 |
| Hold | 15 | 19 | 22 | 24 | 14 |
| Sell | 1 | 2 | 2 | 3 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 23 | 27 | 30 | 33 | 20 |
In the current month, EX9 has received 4 Buy Ratings, 14 Hold Ratings, and 2 Sell Ratings. EX9 average Analyst price target in the past 3 months is 52.97.
EX9 Financial Forecast
HighEUR 1.09
ConsensusEUR 0.86
LowEUR 0.49
EX9 Earnings Forecast
Next quarter’s earnings estimate for EX9 is EUR 0.86 with a range of EUR 0.49 to EUR 1.09. The previous quarter’s EPS was EUR 0.84. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 615M
ConsensusEUR 590M
LowEUR 572M
EX9 Sales Forecast
Next quarter’s sales forecast for EX9 is EUR 589.56M with a range of EUR 571.53M to EUR 615.14M. The previous quarter’s sales results were EUR 589.79M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
EX9 Stock Forecast FAQ
What is DE:EX9’s average 12-month price target, according to analysts?
Based on analyst ratings, Exelixis’s 12-month average price target is €52.97.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Exelixis a Buy, Sell or Hold?
Exelixis has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 9 hold ratings and 1 sell ratings.
What is Exelixis’s share price target?
The average share price target for Exelixis is €52.97. This is based on 15 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €69.84, and the lowest forecast is €36.71. The average share price target represents a 14.03% decrease from the current price of €61.61.
What do analysts say about Exelixis?
Exelixis’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Street analysts.
How can I buy shares of Exelixis?
To buy shares of DE:EX9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
